662 related articles for article (PubMed ID: 23012466)
21. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.
Chen L; Luo Q; Shen Y; Yu Y; Yuan Z; Lu H; Zhu R
J Nucl Med; 2008 Dec; 49(12):1952-7. PubMed ID: 18997044
[TBL] [Abstract][Full Text] [Related]
22. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma.
Yamamoto Y; Nishiyama Y; Monden T; Matsumura Y; Satoh K; Ohkawa M
J Nucl Med; 2003 Dec; 44(12):1905-10. PubMed ID: 14660715
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer.
Aide N; Heutte N; Rame JP; Rousseau E; Loiseau C; Henry-Amar M; Bardet S
J Clin Endocrinol Metab; 2009 Jun; 94(6):2075-84. PubMed ID: 19276233
[TBL] [Abstract][Full Text] [Related]
24. [Impact of 131I SPECT/CT on the management of differentiated thyroid carcinoma outpatients with radioablation].
Mizokami D; Kosuda S; Shiotani A; Kinoshita F; Saotome K; Morozumi K
Nihon Jibiinkoka Gakkai Kaiho; 2014 May; 117(5):673-80. PubMed ID: 24956745
[TBL] [Abstract][Full Text] [Related]
25. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
26. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma.
Ruf J; Lehmkuhl L; Bertram H; Sandrock D; Amthauer H; Humplik B; Ludwig Munz D; Felix R
Nucl Med Commun; 2004 Dec; 25(12):1177-82. PubMed ID: 15640775
[TBL] [Abstract][Full Text] [Related]
27. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
28. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 131I whole-body scintigraphy.
Donahue KP; Shah NP; Lee SL; Oates ME
Radiology; 2008 Mar; 246(3):887-94. PubMed ID: 18309016
[TBL] [Abstract][Full Text] [Related]
29. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
30. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation. A bicentric study.
Ilhan H; Mustafa M; Bartenstein P; Kuwert T; Schmidt D
Nuklearmedizin; 2016 Dec; 55(6):221-227. PubMed ID: 27588323
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
32. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
33. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹⁸F-FDG PET/CT in the detection of metastatic thyroid cancer.
Oh JR; Byun BH; Hong SP; Chong A; Kim J; Yoo SW; Kang SR; Kim DY; Song HC; Bom HS; Min JJ
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1459-68. PubMed ID: 21505897
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
Iwano S; Kato K; Ito S; Tsuchiya K; Naganawa S
Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of (99m)Tc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients.
Chantadisai M; Kingpetch K
Ann Nucl Med; 2014 Aug; 28(7):674-82. PubMed ID: 24889127
[TBL] [Abstract][Full Text] [Related]
37. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
38. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma.
Wu X; Gu H; Gao Y; Li B; Fan R
Nucl Med Commun; 2018 Jan; 39(1):22-27. PubMed ID: 29135721
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of SPECT/CT for equivocal findings on (131)I whole-body scan in a patient with differentiated papillary thyroid cancer.
Choi B; Kim DH; Son SH; Zeon S; Ahn BC
Clin Nucl Med; 2014 Feb; 39(2):e160-2. PubMed ID: 23531738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]